Showing 2251-2260 of 3858 results for "".
Everything Old Is New Again: Re-assessing IPL
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/everything-old-is-new-again-re-assessing-ipl/23013/Long-term IPL use may turn the tables on aging skin.PRP: What Dermatologists Should Know
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/prp-what-dermatologists-should-know/20333/Long used in orthopedic medicine and made popular on social media, PRP has science to support its use in dermatology.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaHow NEMLUVIO® Works
https://practicaldermatology.com/programs/nemluvio-peer-network/how-nemluvio-works/37226/Learn how NEMLUVIO® works to directly block IL-31RA from Dr Peter Lio, a leading dermatologist, with extensive experience in treating neuroimmune skin diseases.Understanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://practicaldermatology.com/series/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.The Role of GLP-1RAs in Treating Inflammatory Dermatologic Diseases
https://practicaldermatology.com/issues/novemberdecember-2025/the-role-of-glp-1ras-in-treating-inflammatory-dermatologic-diseases/48899/Herein, we review the benefits and risks of GLP-1RAs with a focus on these 3 chronic inflammatory conditions.Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethAAD Wrap: What To Know from Dermatology’s Biggest Meeting
https://practicaldermatology.com/issues/april-2025/aad-wrap-what-to-know-from-dermatologys-biggest-meeting/35623/The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together the dermatology community this past March to exchange groundbreaking research, innovative treatments, and technological advancements. For 4 days in Orlando, the meeting served as the hub of the dermatology profession, del